Azeliragon (TTP488)

Catalog No.S6415 Synonyms: PF-04494700

For research use only.

Azeliragon (TTP488, PF-04494700) is an orally bioavailable small molecule that inhibits the receptor for advanced glycation endproducts (RAGE), which is an immunoglobulin-like cell surface receptor overexpressed in brain tissues of patients with AD.

Azeliragon (TTP488) Chemical Structure

CAS No. 603148-36-3

Selleck's Azeliragon (TTP488) has been cited by 3 Publications

Purity & Quality Control

Related Other Products

Biological Activity

Description Azeliragon (TTP488, PF-04494700) is an orally bioavailable small molecule that inhibits the receptor for advanced glycation endproducts (RAGE), which is an immunoglobulin-like cell surface receptor overexpressed in brain tissues of patients with AD.
Targets
RAGE [1]
In vivo

Preclinical studies in animal models of alzheimer disease (tgAPPSwedish/London) have shown azeliragon to decrease Aβ plaque deposition; reduce total Aβ brain concentration while increasing plasma Aβ levels; decrease sAPPβ while increasing sAPPα; reduce levels of inflammatory cytokines; and slow cognitive decline and improve cerebral blood flow[1].

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 532.12
Formula

C32H38ClN3O2

CAS No. 603148-36-3
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCCCC1=NC(=CN1C2=CC=C(C=C2)OC3=CC=C(C=C3)Cl)C4=CC=C(C=C4)OCCCN(CC)CC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00287183 Completed Drug: PF-04494700 (TTP488)|Other: Placebo Diabetic Nephropathy Pfizer February 2006 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Azeliragon (TTP488) | Azeliragon (TTP488) supplier | purchase Azeliragon (TTP488) | Azeliragon (TTP488) cost | Azeliragon (TTP488) manufacturer | order Azeliragon (TTP488) | Azeliragon (TTP488) distributor